InvestMoat
Telehealth | DTC SubscriptionSpeculative Growth

Hims & Hers Health

HIMS~$5.8B capAnalysed Nov 10

Hold

Hold for Long-Term Compounding

71
Moat54
Growth73
Val88
0255075100

Combined average of Moat (AI Resilience), Growth, and Valuation scores.

54/100

DTC telehealth subscription brand with vertical pharmacy and multi-category bundle — narrow brand moat. March 2026 Novo Nordisk branded GLP-1 partnership resolved the compounding lawsuit overhang but compressed weight-loss unit economics; July 2026 FTC privacy/billing suit re-opens regulatory tail risk.

Hims's moat is brand recognition + vertical pharmacy + multi-category subscription bundling in telehealth — real but narrow, with regulatory exposure now centred on FTC consumer-protection claims and branded-GLP-1 margin mix rather than compounded-semaglutide enforcement alone:

  • DTC Brand Reach in Targeted Categories: Hims has built genuine brand awareness in men's hair loss, sexual health, mental health, weight-loss, and women's hormonal health. The marketing flywheel and CAC-LTV economics in established categories remain the franchise's core; Q1 subscribers reached 2.58M (+9% YoY) even as U.S. revenue dipped on the GLP-1 mix shift.
  • Vertical Pharmacy and Branded GLP-1 Access: Hims operates its own compounding pharmacies, but the March 2026 Novo Nordisk collaboration put FDA-approved Ozempic and Wegovy (injectable and oral) on the platform at Novo self-pay prices and ended Novo's patent suit. Compounded GLP-1 is now limited to clinically necessary cases — a cleaner legal channel at structurally lower margin than 2024 compounded semaglutide.
  • Clinical Network and International Scale: A national provider network plus ZAVA, Livewell, and the June 2026 Eucalyptus close (Australia/Canada/Germany/Japan/UK footprint; ~850K prior customers) extend the closed-loop subscription stack. Switching costs for the patient remain low; convenience-and-pricing UX vs traditional care is the retention lever.

Hims is a brand-and-bundle moat business in a regulated industry — AI is neutral-to-positive on cost (provider productivity) but the dominant moat questions are regulatory (now FTC + compounding history) and competitive. The Novo partnership cleans up GLP-1 legality at the cost of margin; the thesis remains execution-and-category-expansion, appropriately sized as speculative growth.

56.6 resilient · 43.1 vulnerable · 80/20 = 53.9 · = 54

Open a moat to read its note.

AI-Vulnerable Moats1 intact · 3 weakened · 1 N/A
AI-Resilient Moats3 intact · 1 weakened · 3 N/A

Hims's moats hold where they are. The multi-category subscription bundle and the brand carry the score, and the March 2026 Novo collaboration put branded GLP-1s on the platform rather than taking the category away. The FTC privacy and billing suit is a live risk to the data and brand pillars, but it is charged in the growth keyRisk until an outcome lands, so no pillar is called in either direction.

No moat trending · 54 holds

Is Hims & Hers Health stock a buy?

We rate Hims & Hers Health Hold, with a composite score of 71/100: moat 54, growth 73 and valuation 88. The valuation score is struck against our bear, base and bull targets and moves with the price.

What is Hims & Hers Health's moat?

Hims & Hers Health scores 54/100 on moat. DTC telehealth subscription brand with vertical pharmacy and multi-category bundle — narrow brand moat.

How fast is Hims & Hers Health expected to grow?

We estimate 20-28% a year over the next three to five years, for a growth score of 73/100.

What is Hims & Hers Health's price target?

Our base case is $35, with $22 in the bear case and $68 in the bull case.